Ufp Technologies AI Stock Analysis
Want to see UFPT full AI Analyst Report?
Ufp Technologies (UFPT) AI Stock Analysis
Ufp Technologies
(NASDAQ:UFPT)
UFPT scores well on financial quality (strong margins, ROE, and improving leverage) and has supportive trend signals (trading above key moving averages with positive MACD). The score is held back mainly by a relatively high P/E (~30.7) and signs of growth normalization/uneven cash conversion, alongside earnings-call risks around AJR transfer delays, elevated SG&A, and a flat-to-down robotic surgery outlook for 2026.
Ufp Technologies Key Performance Indicators (KPIs)
Net Sales by MarketRevenue distribution across the company’s end markets (for example, food, medical, industrial). Reveals where UFP Technologies gets its sales, how exposed it is to particular industries or economic cycles, and whether growth or weakness is concentrated in a few markets — key for assessing demand risk and upside potential from market diversification.
Medical has become the clear growth engine, with a step-up in scale followed by sustained expansion, while Non-Medical remains materially smaller and has not regained its earlier momentum. The latest acceleration supports management’s view of broad-based MedTech demand, including launch programs and capacity additions, though the expected normalization toward 6–9% organic growth suggests investors should not extrapolate the recent surge. Robotic-surgery program ramps provide an additional medium-term catalyst for the Medical market.
Ufp Technologies (UFPT) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.37B
- Dividend Yield
- ―
- Average Volume (3M)
- 112.04K
- Price to Earnings (P/E)
- 30.9
- Beta (1Y)
- 0.99
- Revenue Growth
- 8.62%
- EPS Growth
- 13.50%
- Country
- US
- Employees
- 4,846
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Ufp Technologies Business Overview & Revenue Model
Company Description
UFP Technologies, Inc. specializes in the engineering and custom fabrication of components, subassemblies, finished products, and packaging, primarily utilizing advanced foams, films, and plastics. A significant portion of its business is dedicated t...
How the Company Makes Money
UFPT makes money primarily by manufacturing and selling custom-engineered products and components to customers, with its largest revenue stream coming from medical device-related programs. Revenue is generally generated through (1) long-term or progr...
Ufp Technologies Earnings Call Summary
The call was predominantly positive, supported by double-digit sales and MedTech growth, higher gross margins and adjusted earnings, strong operating cash flow, broad customer demand, capacity investments and an active acquisition pipeline. The main challenges were delayed AJR transfers, continued AJR margin headwinds, higher SG&A and a flat-to-down 2026 outlook for robotic surgery, along with expected seasonal softness in the fourth quarter.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management does not give quarterly or annual guidance, but remains comfortable with the organic growth range of 6% to 9% and the overall 12% to 18% with regard to organic and inorganic growth combined; 2026 is a flat to down year in robotic surgery, Q4 is traditionally softer, DAS Medical is adding capacity ahead of anticipated double-digit growth next year, and additional AJR transfer activity is expected in '27. Management is comfortable in the gross-margin range of 28% to 31% and is settling in at that 29%, expects SG&A investments to moderate as the business grows, and can borrow at 3.25x EBITDA under its current credit facility.
Ufp Technologies Financial Statement Overview
Summary
Strong overall fundamentals: high profitability with healthy gross (~29%), operating (~15%) and net (~12%) margins, solid ROE (mid-to-high teens), and improving leverage (TTM debt-to-equity ~0.20). The main offsets are slowing top-line momentum in the latest TTM period and slightly weaker/uneven cash conversion (TTM operating cash flow below net income and down vs. 2025), which reduces confidence in near-term acceleration.
Income Statement
86Very PositiveBalance Sheet
84Very PositiveCash Flow
72Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 649.51M | 602.80M | 504.42M | 400.07M | 353.79M | 206.32M |
| Gross Profit | 188.01M | 170.41M | 146.69M | 112.22M | 90.26M | 51.11M |
| EBITDA | 115.36M | 111.47M | 95.80M | 68.95M | 67.37M | 29.65M |
| Net Income | 76.53M | 68.31M | 58.98M | 44.92M | 41.79M | 15.89M |
Balance Sheet | ||||||
| Total Assets | 682.63M | 655.08M | 629.00M | 404.14M | 378.19M | 334.13M |
| Cash, Cash Equivalents and Short-Term Investments | 20.63M | 20.30M | 13.45M | 5.26M | 4.45M | 11.12M |
| Total Debt | 116.54M | 154.48M | 206.03M | 46.04M | 68.37M | 84.36M |
| Total Liabilities | 196.92M | 231.20M | 286.24M | 118.05M | 140.65M | 139.69M |
| Stockholders Equity | 485.71M | 423.88M | 342.76M | 286.09M | 237.54M | 194.45M |
Cash Flow | ||||||
| Free Cash Flow | 63.51M | 78.98M | 56.94M | 30.84M | 3.96M | 8.90M |
| Operating Cash Flow | 74.20M | 91.91M | 66.59M | 41.33M | 17.74M | 14.29M |
| Investing Cash Flow | -17.52M | -27.60M | -210.16M | -10.49M | 1.29M | -101.46M |
| Financing Cash Flow | -53.93M | -58.16M | 152.39M | -30.02M | -25.89M | 74.05M |
Ufp Technologies Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UFPT, the sentiment is Positive. The current price of 305.65 is above the 20-day moving average (MA) of 300.00, above the 50-day MA of 294.01, and above the 200-day MA of 252.41, indicating a bullish trend. The MACD of 3.09 indicates Positive momentum. The RSI at 53.04 is Neutral, neither overbought nor oversold. The STOCH value of 25.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UFPT.
Ufp Technologies Risk Analysis
Ufp Technologies disclosed 35 risk factors in its most recent earnings report. Ufp Technologies reported the most risks in the "Macro & Political" category.
Latest Risks Added
3 New RisksUfp Technologies Peers Comparison
Overall Rating
UFPT75Outperform
ITGR63.5Neutral
CNMD63Neutral
NSYS63Neutral
VREX57Neutral
IART43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | $2.30B | 30.87 | 16.90% | ― | 8.62% | 13.50% | |
| 64Neutral | $4.31B | 42.23 | 6.02% | ― | -0.33% | 20.67% | |
| 63Neutral | $1.43B | 19.84 | 7.07% | ― | 1.93% | 16.93% | |
| 63Neutral | $32.84M | 17.69 | 5.14% | ― | 9.04% | ― | |
| 57Neutral | $770.71M | 34.57 | 4.60% | ― | 5.31% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $1.05B | 82.60 | 1.24% | ― | 0.84% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| UFPT | Ufp Technologies | 305.65 | 95.80 | 45.65% | |
| CNMD | Conmed Corporation | 48.01 | 7.38 | 18.16% | |
| ITGR | Integer Holdings | 126.70 | 58.57 | 85.97% | |
| IART | Integra Lifesciences | 13.86 | 2.81 | 25.43% | |
| NSYS | Nortech | 11.46 | 4.65 | 68.28% | |
| VREX | Varex Imaging Corporation | 18.15 | 7.86 | 76.38% |
Ufp Technologies Corporate Events
UFP Technologies Updates Investor Presentation and Strategic Outlook
NeutralIn August 2026, UFP Technologies released updated investor presentation materials outlining its business activities and strategic focus for use in meetings with investors and other audiences. The presentation emphasizes the company’s role in multiple...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
